Atara Biotherapeutics (ATRA)
(Real Time Quote from BATS)
$8.23 USD
-0.04 (-0.48%)
Updated Aug 7, 2024 10:12 AM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Atara Biotherapeutics (ATRA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$30.33 | $55.00 | $11.00 | 266.75% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Atara Biotherapeutics comes to $30.33. The forecasts range from a low of $11.00 to a high of $55.00. The average price target represents an increase of 266.75% from the last closing price of $8.27.
Analyst Price Targets (3 )
Broker Rating
Atara Biotherapeutics currently has an average brokerage recommendation (ABR) of 2.71 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 2.71 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, two are Strong Buy, representing 28.57% of all recommendations. A month ago, Strong Buy represented 28.57%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 4 | 4 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 2 | 2 |
ABR | 2.71 | 2.71 | 2.71 | 3.00 | 3.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/17/2024 | Goldman Sachs | Salveen Richter | Strong Sell | Strong Sell |
7/12/2024 | Mizuho SecuritiesUSA | Salim Syed | Hold | Hold |
4/1/2024 | Cowen & Co. | Philip M Nadeau | Strong Buy | Strong Buy |
4/1/2024 | Not Identified | Not Identified | Hold | Hold |
3/28/2024 | Canaccord Genuity | John L Newman | Strong Buy | Strong Buy |
3/1/2024 | H.C. Wainwright & Co. | Robert Burns | Hold | Hold |
11/9/2023 | Evercore Partners | Jonathan Miller | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.71 |
ABR (Last week) | 2.71 |
# of Recs in ABR | 7 |
Average Target Price | $30.33 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 93 of 253 |
Current Quarter EPS Est: | -1.25 |